BRPI0507972A - composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada - Google Patents
composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embaladaInfo
- Publication number
- BRPI0507972A BRPI0507972A BRPI0507972-1A BRPI0507972A BRPI0507972A BR PI0507972 A BRPI0507972 A BR PI0507972A BR PI0507972 A BRPI0507972 A BR PI0507972A BR PI0507972 A BRPI0507972 A BR PI0507972A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- inhibiting
- proteolytic activity
- cleavage enzyme
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000003776 cleavage reaction Methods 0.000 title 1
- 230000002797 proteolythic effect Effects 0.000 title 1
- 230000007017 scission Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Abstract
COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODO PARA INIBIçãO DA ATIVIDADE PROTEOLìTICA DE UMA ENZIMA DE CLIVAGEM PóS PROLINA E COMPOSIçãO FARMACêUTICA EMBALADA A presente invenção se refere à inibidores de enzimas de clivagem pós prolina, tais como inibidores de dipeptidilpeptidase IV, assim como as composições farmacêuticas do mesmo, e métodos de usos dos referidos inibidores. Em particular, os inibidores da presente invenção são aprimorados em relação aos da técnica anterior por meio da seleção de classes particulares de cadeias laterais na posição P1 e/ou P2 do inibidor que contém uma fração de ácido carboxílico. Os compostos da presente invenção podem apresentar um melhor índice terapêutico, em parte em virtude da toxicidade reduzida e/ou da especificidade aprimorada para a protease alvo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54722704P | 2004-02-23 | 2004-02-23 | |
| US59933604P | 2004-08-06 | 2004-08-06 | |
| PCT/US2005/006128 WO2005082348A2 (en) | 2004-02-23 | 2005-02-23 | Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507972A true BRPI0507972A (pt) | 2007-07-24 |
Family
ID=34915595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507972-1A BRPI0507972A (pt) | 2004-02-23 | 2005-02-23 | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20050203027A1 (pt) |
| EP (1) | EP1729757A2 (pt) |
| JP (1) | JP4781347B2 (pt) |
| KR (2) | KR20130016435A (pt) |
| AU (1) | AU2005216970B2 (pt) |
| BR (1) | BRPI0507972A (pt) |
| CA (1) | CA2558106A1 (pt) |
| IL (2) | IL177644A0 (pt) |
| MX (1) | MXPA06009589A (pt) |
| NO (1) | NO20064307L (pt) |
| RU (1) | RU2379315C2 (pt) |
| TW (1) | TWI382836B (pt) |
| WO (1) | WO2005082348A2 (pt) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE357509T1 (de) | 1997-09-29 | 2007-04-15 | Point Therapeutics Inc | Stimulierung von hämatopoietischen zellen im vitro |
| US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| WO2003045228A2 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
| US7691967B2 (en) * | 2002-04-30 | 2010-04-06 | Trustees Of Tufts College | Smart pro-drugs of serine protease inhibitors |
| AU2005216970B2 (en) * | 2004-02-23 | 2011-07-07 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism |
| US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
| WO2006034435A2 (en) * | 2004-09-21 | 2006-03-30 | Point Therapeutics, Inc. | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US8093017B2 (en) * | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| CA2633167A1 (en) * | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| JP5270369B2 (ja) | 2005-12-19 | 2013-08-21 | タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ | ソフトプロテアーゼ抑制剤およびそのプロソフト型 |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| WO2008118848A1 (en) * | 2007-03-23 | 2008-10-02 | Trustees Of Tufts College | N-substituted peptidomimetic inhibitors of dipeptidylpeptidase iv |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| EP2400976B1 (en) * | 2009-02-27 | 2016-12-14 | Trustees Of Tufts College | Soft protease inhibitors, and pro-soft forms thereof |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| CA2795513A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| PL2753334T3 (pl) | 2011-08-30 | 2022-12-12 | Trustees Of Tufts College | Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2014008374A2 (en) * | 2012-07-06 | 2014-01-09 | Thetis Pharmaceuticals Llc | Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents |
| WO2014068023A1 (en) | 2012-11-02 | 2014-05-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Dpp8 and dpp9 peptide inhibitors |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CN107750467A (zh) * | 2015-06-23 | 2018-03-02 | 瑞典爱立信有限公司 | 提前的多播广播多媒体服务（mbms）公告 |
| PL3472149T3 (pl) | 2016-06-21 | 2024-02-12 | Orion Ophthalmology LLC | Heterocykliczne pochodne prolinamidu |
| US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
| US11583516B2 (en) * | 2016-09-07 | 2023-02-21 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
| PT3571208T (pt) * | 2017-01-18 | 2021-04-13 | Principia Biopharma Inc | Inibidores do imunoproteassoma |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| EP3710458B1 (en) | 2017-11-16 | 2026-03-25 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| ES2928787T3 (es) | 2017-11-16 | 2022-11-22 | Principia Biopharma Inc | Inhibidores del inmunoproteasoma |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250720A (en) * | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
| US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| JPH0223849A (ja) * | 1988-06-08 | 1990-01-26 | Morishita Pharmaceut Co Ltd | ペプチド含有栄養輸液組成物 |
| DK716188D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| JPH03264525A (ja) * | 1990-03-14 | 1991-11-25 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| US5189016A (en) * | 1990-05-18 | 1993-02-23 | Clintec Nutrition Co. | Nutrient compositions containing peptides and method for administering the same |
| US6825169B1 (en) * | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
| US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| ATE357509T1 (de) * | 1997-09-29 | 2007-04-15 | Point Therapeutics Inc | Stimulierung von hämatopoietischen zellen im vitro |
| CA2306812A1 (en) * | 1997-10-23 | 1999-04-29 | Pharmaprint, Inc. | Pharmaceutical grade garlic |
| EP2583675A1 (en) * | 1998-02-02 | 2013-04-24 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| IL139247A0 (en) * | 1998-05-04 | 2001-11-25 | Point Therapeutics Inc | Hematopoietic stimulation |
| JP2002517401A (ja) * | 1998-06-05 | 2002-06-18 | ポイント セラピューティクス， インコーポレイテッド | 環状ボロプロリン化合物 |
| US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| US6410556B1 (en) * | 1999-09-10 | 2002-06-25 | Novo Nordisk A/S | Modulators of protein tyrosine phosphateses (PTPases) |
| KR20080067009A (ko) * | 2000-03-31 | 2008-07-17 | 프로시디온 리미티드 | 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물 |
| JP2002023849A (ja) * | 2000-06-30 | 2002-01-25 | Ishikawajima Harima Heavy Ind Co Ltd | 移動体の位置決め方法 |
| WO2002053519A2 (en) * | 2001-01-08 | 2002-07-11 | Mediquest Therapeutics, Inc. | Hydrophobic polyamine analogs and methods for their use |
| WO2003045228A2 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
| EP2316470A3 (en) * | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| JP2003264525A (ja) * | 2002-03-11 | 2003-09-19 | Alps Electric Co Ltd | Ｏｆｄｍ受信装置 |
| WO2004004661A2 (en) * | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| ATE549028T1 (de) * | 2003-05-15 | 2012-03-15 | Tufts College | Stabile analoga von glp-1 |
| EP1699777B1 (en) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| SG134333A1 (en) * | 2003-11-12 | 2007-08-29 | Phenomix Corp | Heterocyclic boronic acid compounds |
| AU2005216970B2 (en) * | 2004-02-23 | 2011-07-07 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism |
| US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
| TWI297341B (en) * | 2005-09-13 | 2008-06-01 | Univ Nat Taiwan Normal | A copolymer which is used as a dispersing agent for titanate-based ceramic colloids |
-
2005
- 2005-02-23 AU AU2005216970A patent/AU2005216970B2/en not_active Ceased
- 2005-02-23 KR KR1020137002340A patent/KR20130016435A/ko not_active Ceased
- 2005-02-23 CA CA002558106A patent/CA2558106A1/en not_active Abandoned
- 2005-02-23 KR KR1020067019660A patent/KR101292707B1/ko not_active Expired - Fee Related
- 2005-02-23 TW TW094105369A patent/TWI382836B/zh not_active IP Right Cessation
- 2005-02-23 JP JP2007501012A patent/JP4781347B2/ja not_active Expired - Fee Related
- 2005-02-23 RU RU2006133899/04A patent/RU2379315C2/ru not_active IP Right Cessation
- 2005-02-23 WO PCT/US2005/006128 patent/WO2005082348A2/en not_active Ceased
- 2005-02-23 BR BRPI0507972-1A patent/BRPI0507972A/pt not_active IP Right Cessation
- 2005-02-23 MX MXPA06009589A patent/MXPA06009589A/es active IP Right Grant
- 2005-02-23 US US11/065,001 patent/US20050203027A1/en not_active Abandoned
- 2005-02-23 EP EP05723831A patent/EP1729757A2/en not_active Withdrawn
-
2006
- 2006-08-22 IL IL177644A patent/IL177644A0/en unknown
- 2006-09-22 NO NO20064307A patent/NO20064307L/no not_active Application Discontinuation
-
2008
- 2008-11-03 US US12/263,679 patent/US20090062235A1/en not_active Abandoned
-
2011
- 2011-05-16 US US13/108,461 patent/US20110218142A1/en not_active Abandoned
-
2012
- 2012-01-31 IL IL217853A patent/IL217853A0/en unknown
-
2013
- 2013-09-24 US US14/035,144 patent/US20140018545A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006133899A (ru) | 2008-03-27 |
| MXPA06009589A (es) | 2007-03-26 |
| US20110218142A1 (en) | 2011-09-08 |
| RU2379315C2 (ru) | 2010-01-20 |
| TW200538096A (en) | 2005-12-01 |
| AU2005216970A1 (en) | 2005-09-09 |
| NO20064307L (no) | 2006-11-15 |
| AU2005216970B2 (en) | 2011-07-07 |
| US20090062235A1 (en) | 2009-03-05 |
| IL217853A0 (en) | 2012-03-29 |
| US20050203027A1 (en) | 2005-09-15 |
| IL177644A0 (en) | 2008-04-13 |
| WO2005082348A3 (en) | 2005-12-29 |
| JP2007523216A (ja) | 2007-08-16 |
| EP1729757A2 (en) | 2006-12-13 |
| KR101292707B1 (ko) | 2013-08-02 |
| JP4781347B2 (ja) | 2011-09-28 |
| TWI382836B (zh) | 2013-01-21 |
| KR20070030181A (ko) | 2007-03-15 |
| US20140018545A1 (en) | 2014-01-16 |
| CA2558106A1 (en) | 2005-09-09 |
| WO2005082348A2 (en) | 2005-09-09 |
| KR20130016435A (ko) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507972A (pt) | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada | |
| ECSP20027480A (es) | Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa | |
| BRPI0508085A (pt) | compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c | |
| BR112012011072A2 (pt) | inibidores de n1-pirazolospirocetona acetil-coa carboxilase | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| UY27391A1 (es) | Inhibidores de polimerasa virica | |
| BR0308081A (pt) | Inibidores de histona desacetilase | |
| CL2009000967A1 (es) | Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente. | |
| BRPI0507971A (pt) | composto, composição farmacêutica, uso de um composto,método para inibir a atividade proteolìtica de uma enzima de clivagem pós-prolina e remédio empacotado | |
| BRPI0609121B8 (pt) | 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2 | |
| BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
| BR0212510A (pt) | Inibidor de histona desacetilase, composto e composição | |
| CO6341555A2 (es) | Compuestos quimicos 251 | |
| BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| CR9462A (es) | Inhibidores de la dipeptidil peptidasa-iv | |
| IL198979A (en) | Enzyme inhibitors diacylglycerol o-acetyltransferase type 1 | |
| BR0305426A (pt) | Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos | |
| WO2008063671A3 (en) | Heterobicyclic metalloprotease inhibitors | |
| BRPI0415960A (pt) | composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, uso de um composto,e, método para produzir um composto | |
| UY28674A1 (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| BRPI0416287A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização | |
| BR0308613A (pt) | Combinação de compostos orgânicos | |
| BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| NI200900052A (es) | Heterocíclicos derivados de los inhibidores de metaloproteasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |